Quince Therapeutics (QNCX)

• Market cap: $43.6M
• 1 day: 6.60%
• 5 days: 7.62%
• 1 month: -19.29%
• 3 months: -28.93%
• 6 months: -5.04%
• Year to date: -39.89%
• 1 year: 6.60%
• 5 years: -97.48%
• 10 years: -96.56%
• Sector: Healthcare
• Industry: Biotechnology

About: Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

Employees: 36

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

24,000% more call options, than puts

Call options by funds: $1.69M | Put options by funds: $7K

136% more capital invested

Capital invested by funds: $4.04M [Q3] → $9.55M (+$5.51M) [Q4]

100% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 5

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

6% more funds holding

Funds holding: 33 [Q3] → 35 (+2) [Q4]

0.39% less ownership

Funds ownership: 12.0% [Q3] → 11.61% (-0.39%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 254% upside
• Avg. target: $7 519% upside
• High target: $10 785% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 22% 1-year accuracy 81 / 364 met price target	254% upside $4	Buy Maintained	25 Mar 2025
Oppenheimer Leland Gershell 40% 1-year accuracy 18 / 45 met price target	785% upside $10	Outperform Initiated	24 Mar 2025